Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00841204 · ClinicalTrials.gov registry record · Phase 2
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
A Phase 2 study of Precancerous Condition, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT00841204 is a Phase 2 study of Precancerous Condition that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 619-participant average among 15 other Precancerous Condition trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00841204, a Phase 2 study of Precancerous Condition, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more effective than a placebo in preventing melanoma in individuals with many moles and abnormal moles.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- OTHER placebo
- DRUG sulindac
Study Locations (2)
Arizona
- University of Arizona Health Sciences Center - Tucson
California
- Stanford University Hospitals and Clinics - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00841204
The ClinicalTrials.gov registry entry for NCT00841204 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 619-participant average among 15 other Precancerous Condition trials with a reported enrollment target (92% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Precancerous Condition appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00841204 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00841204 about?
NCT00841204 is a clinical study titled "Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma". This randomized phase II trial is studying how well sulindac works in preventing melanoma in healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether sulindac is more ef...
What is the current status of trial NCT00841204?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2009-02. Estimated completion is 2011-02.
What conditions does trial NCT00841204 study?
This clinical trial studies the following conditions: Precancerous Condition.
What interventions are being tested in trial NCT00841204?
The interventions under investigation include: laboratory biomarker analysis (OTHER), placebo (OTHER), sulindac (DRUG).
Who is sponsoring clinical trial NCT00841204?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00841204 being conducted?
This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Precancerous Condition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lovastatin in Treating Patients At High Risk of Melanoma
COMPLETED · Phase 2
-
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
COMPLETED · Phase 2
-
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
COMPLETED · Phase 2
-
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
COMPLETED · Phase 2
-
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RECRUITING
-
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.